These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 15930029

  • 1. Biological properties of a human compact anti-ErbB2 antibody.
    De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P, D'Alessio G.
    Carcinogenesis; 2005 Nov; 26(11):1890-5. PubMed ID: 15930029
    [Abstract] [Full Text] [Related]

  • 2. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor.
    Troise F, Cafaro V, Giancola C, D'Alessio G, De Lorenzo C.
    FEBS J; 2008 Oct; 275(20):4967-79. PubMed ID: 18795950
    [Abstract] [Full Text] [Related]

  • 3. Effects of a human compact anti-ErbB2 antibody on prostate cancer.
    Malara AE, Fedele C, Aloj L, Arra C, Laccetti P, D'Alessio G, De Lorenzo C.
    Oncol Rep; 2012 Jul; 28(1):297-302. PubMed ID: 22505344
    [Abstract] [Full Text] [Related]

  • 4. Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.
    De Lorenzo C, Troise F, Cafaro V, D'Alessio G.
    Br J Cancer; 2007 Nov 19; 97(10):1354-60. PubMed ID: 17923870
    [Abstract] [Full Text] [Related]

  • 5. A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.
    Borriello M, Laccetti P, Terrazzano G, D'Alessio G, De Lorenzo C.
    Br J Cancer; 2011 May 24; 104(11):1716-23. PubMed ID: 21559015
    [Abstract] [Full Text] [Related]

  • 6. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
    Shi M, Zhang L, Gu HT, Jiang FQ, Qian L, Yu M, Chen GJ, Luo Q, Shen BF, Guo N.
    Acta Pharmacol Sin; 2007 Oct 24; 28(10):1611-20. PubMed ID: 17883948
    [Abstract] [Full Text] [Related]

  • 7. A novel ErbB2 epitope targeted by human antitumor immunoagents.
    Troise F, Monti M, Merlino A, Cozzolino F, Fedele C, Russo Krauss I, Sica F, Pucci P, D'Alessio G, De Lorenzo C.
    FEBS J; 2011 Apr 24; 278(7):1156-66. PubMed ID: 21288302
    [Abstract] [Full Text] [Related]

  • 8. A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent.
    De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R, D'Alessio G.
    Br J Cancer; 2004 Sep 13; 91(6):1200-4. PubMed ID: 15305184
    [Abstract] [Full Text] [Related]

  • 9. Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent.
    De Lorenzo C, Di Malta C, Calì G, Troise F, Nitsch L, D'Alessio G.
    FEBS Lett; 2007 Jan 23; 581(2):296-300. PubMed ID: 17208233
    [Abstract] [Full Text] [Related]

  • 10. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.
    Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC.
    Biochem Biophys Res Commun; 2001 Jan 12; 280(1):274-9. PubMed ID: 11162510
    [Abstract] [Full Text] [Related]

  • 11. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents.
    Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, Laccetti P, Hrelia S, D'Alessio G, De Lorenzo C.
    FASEB J; 2009 Sep 12; 23(9):3171-8. PubMed ID: 19417081
    [Abstract] [Full Text] [Related]

  • 12. A novel human antitumor dimeric immunoRNase.
    Riccio G, Borriello M, D'Alessio G, De Lorenzo C.
    J Immunother; 2008 Jun 12; 31(5):440-5. PubMed ID: 18463541
    [Abstract] [Full Text] [Related]

  • 13. A new human antitumor immunoreagent specific for ErbB2.
    De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D'Alessio G.
    Clin Cancer Res; 2002 Jun 12; 8(6):1710-9. PubMed ID: 12060608
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA, Towers TL, Presta LG, Ravetch JV.
    Nat Med; 2000 Apr 12; 6(4):443-6. PubMed ID: 10742152
    [Abstract] [Full Text] [Related]

  • 19. Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies.
    De Lorenzo C, D'Alessio G.
    FEBS J; 2009 Mar 12; 276(6):1527-35. PubMed ID: 19220462
    [Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.
    Exp Cell Res; 2005 Apr 01; 304(2):604-19. PubMed ID: 15748904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.